Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Resverlogix’s Reprieve: ASSURE Results Suggest RVX-208 Works When Given With Crestor

This article was originally published in The Pink Sheet Daily

Executive Summary

While the ASSURE study failed overall, it turns out that a subset taking the HDL-raising drug candidate with the statin Crestor did benefit from treatment; Resverlogix is now planning to develop the combination.

You may also be interested in...



In Another Blow For HDL Therapies, Cerenis’ CER-001 Stumbles In Phase II

Intravenous HDL mimetic candidate CER-001 misses endpoint for regression of plaque in Phase IIb study, but Cerenis indicates it’s still committed to the therapy.

In Another Blow For HDL Therapies, Cerenis’ CER-001 Stumbles In Phase II

Intravenous HDL mimetic candidate CER-001 misses endpoint for regression of plaque in Phase IIb study, but Cerenis indicates it’s still committed to the therapy.

Dalcetrapib Failure Raises Yet More Questions On Value Of Tinkering With HDL Cholesterol

Termination of the development program for dalcetrapib creates more doubt about the class of CETP inhibitors, long viewed with ambivalence. But important differences in how the drug works compared to rivals leaves room for some to hold out hope for CETP inhibition and the HDL hypothesis in general.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM008605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel